Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 3Recurrence 2Small Cell Lung Carcinoma 1Metastatic Castration-Resistant Prostate Cancer 1Lymphoma, Follicular 1Adenocarcinoma 1

Interventions

Rituximab 25Lenalidomide 21Cyclophosphamide 20Prednisone 14obinutuzumab 12Vincristine 12Doxorubicin 11Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 9Specimen Handling 8ibrutinib 7Biopsy 7fludarabine 6pembrolizumab 5fludarabine phosphate 5Radiotherapy 5Peripheral Blood Stem Cell Transplantation 5zanubrutinib 4venetoclax 4tazemetostat 4Whole-Body Irradiation 4R-CHOP protocol 4Prednisolone 3Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × PF06821497 × 90 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡